Jiangsu Hengrui Pharmaceuticals(600276.SH) received acceptance of the application for the marketing license of SHR4640 tablets.
Hengrui Medicine (600276.SH) announced that the company has received a "Notice of Acceptance" issued by the National Medical Products Administration...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received the "Acceptance Notification" issued by the National Medical Products Administration. The company's application for the market approval of SHR4640 tablets has been accepted by the national drug regulatory authority. The drug is intended for the long-term treatment of primary gout with hyperuricemia.
Related Articles
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.
A-share hot topics in the evening | NVIDIA invests $5 billion in Intel
Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.
A-share hot topics in the evening | NVIDIA invests $5 billion in Intel
Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
RECOMMEND
Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025
Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025
SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025
